Welcome to our dedicated page for Scilex Holding Co SEC filings (Ticker: SCLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scilex Holding Company filings document the regulatory record for an operating biopharmaceutical company with Nasdaq-listed common stock and warrants. Its disclosures cover material-event reports, material agreements, capital-structure matters, security-holder rights, clinical or regulatory updates, operating and financial results and risk-related information connected to its non-opioid pain management products and development activities.
Scilex proxy materials address annual meeting votes, director elections, auditor ratification and amendments to the company’s equity incentive plan. Other filings include Regulation FD and 8-K disclosures, preferred-stock and warrant-related security structure matters, legal-proceeding disclosures and reporting-status items such as notifications tied to annual-report timing and financial-statement preparation.
Scilex Holding Company entered into a stock repurchase agreement with Vivasor Holding Company on July 18, 2026, under which Scilex agreed to sell 6,101,468 shares of Vivasor Series A-1 Preferred Stock and 355,919 shares of Vivasor Series A-2 Preferred Stock that Scilex had acquired in January 2026.
Vivasor will purchase these shares for an aggregate purchase price of $11,999,762.28, payable in cash by wire transfer, by assignment of Datavault AI, Inc. common stock held by a Vivasor subsidiary, or a combination of both. The price will be paid in five tranches between July 18, 2026 and June 30, 2027. The agreement includes customary representations, warranties, covenants and indemnification provisions. Scilex’s Chief Executive Officer, President and Chairperson, Dr. Henry Ji, Ph.D., also serves as Chief Executive Officer of Vivasor.
SCLX Stock Acquisition JV LLC, a Texas entity, reports beneficial ownership of 30,029,378 Scilex Holding Company securities, representing 11.4% of the common stock class when including 14,018 warrant shares that are exercisable within 60 days.
The holdings include 958,263 common shares and 29,057,097 shares of Series A Preferred Stock, which together with the warrants provide aggregate voting power of 19.3%, including 848,106 votes from the preferred stock. The filing notes Scilex’s 1‑for‑35 reverse stock split on April 15, 2025, and discloses that on July 3, 2026, the reporting person agreed to transfer 500,000 Scilex common shares to Quantum Scan Holdings, Inc. in exchange for Q Scan common stock under a letter agreement.
SCLX Stock Acquisition JV LLC, a major holder of Scilex Holding Co, restructured its position by transferring 500,000 shares of common stock to Quantum Scan Holdings, Inc. in exchange for Q Scan common stock under a letter agreement. The transfer price will be based on the Scilex closing price on the Nasdaq Capital Market on the last trading day immediately before the transfer. After this transaction, the reporting entity holds 958,263 Scilex shares, and the reported holdings already reflect a 1-for-35 reverse stock split effective April 15, 2025.
Scilex Holding Company entered into a binding term sheet with iHolding Group LLP for a proposed $100,000,000 equity investment in newly issued common shares. The parties expect a purchase price of $15.00 per share, which would represent approximately 6,666,667 shares if completed.
The proposal is subject to customary due diligence, negotiation and execution of definitive agreements, board and stockholder approvals, regulatory clearances and other closing conditions, and it may be modified or terminated. Scilex currently expects that, if structured as a private placement, the issuance would rely on exemptions under Section 4(a)(2) and Rule 506 of Regulation D. A press release describing the term sheet and intended use of proceeds for strategic growth, product development, acquisitions, working capital and other corporate purposes was furnished as an exhibit.
Scilex Holding Company has signed a binding term sheet to buy 837 Bitcoin from Datavault AI Inc. for $50 million. The assets are currently held in a Biconomy digital wallet, and the deal is structured as a proposed purchase rather than a completed acquisition.
Scilex plans an initial payment of $30 million, with the remaining $20 million in quarterly installments from the fourth quarter of 2026 through December 31, 2028. The company may pay in cash, common stock, publicly traded securities of its subsidiaries, or a mix, at its discretion. The transaction depends on negotiating a definitive agreement, securing approvals, and satisfying customary closing conditions, and may ultimately not be completed.
Scilex Holding Company reported voting results from its 2026 annual stockholder meeting. All Series A preferred shares, totaling 29,057,097, and 5,389,081 common shares were represented, based on 8,491,267 common shares outstanding as of April 28, 2026.
Stockholders elected Dorman Followwill as a Class I director, ratified BPM LLP as independent registered public accounting firm for the year ending December 31, 2026, and approved an amendment to the 2022 Equity Incentive Plan. The plan’s share reserve was increased by 1,300,000 shares to 2,765,789 shares, including the same total available for incentive stock options.
Scilex Holding Company filed a shelf registration to register up to 2,083,067 shares of Common Stock issuable by the company, up to 6,581,004 resale shares to be offered by selling securityholders and up to 490,617 warrants for resale, all to be offered from time to time.
The prospectus states the Company will receive proceeds only from cash exercises of warrants and expects to receive up to $144.9 million assuming full cash exercise of the Warrants and conversion described; resale proceeds will go to the selling securityholders. The filing discloses the Company may use cash proceeds in part to purchase and stake cryptocurrencies as a treasury strategy.
Scilex Holding Company reported a larger quarterly loss while remaining in a significant deficit position. For the three months ended March 31, 2026, net revenue was $8.6M, up from $5.0M a year earlier, but operating expenses of $40.8M drove a loss from operations of $32.2M.
After sizable fair value movements on derivatives, digital assets and equity investments, Scilex recorded a net loss attributable to common stockholders of $43.3M versus $26.1M in 2025. Cash and cash equivalents were $3.4M, with total assets of $293.6M and total liabilities of $547.7M, resulting in stockholders’ deficit of $249.2M. Management disclosed negative working capital of $459.8M and substantial doubt about the company’s ability to continue as a going concern, noting dependence on future financings and growth in sales of ZTlido, ELYXYB and GLOPERBA. The quarter also reflected a $65.3M balance of digital assets (Bitcoin) and an equity-method Datavault investment of $79.1M, with large unrealized and realized valuation swings affecting results.